Virpax Pharmaceuticals Inc
VRPX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$994
Close$
$0.36
118433.3% upside
Current Fair Value
118433.3% upsideUndervalued by 118433.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $994.00 |
|---|---|
| Enterprise Value | $-1,512,063.00 |
| Earnings per Share | $-70.91 |
| Beta | 2.44 |
| Outstanding Shares | 4,254,403 |
Return
| Return on Equity | 1320.61% |
|---|---|
| Return on Assets | -775.72% |
| Return on Invested Capital | 1682.91% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 19, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Virpax Pharmaceuticals Inc
2 employees
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery plat...